Nervous System Origin Or Derivative Patents (Class 435/368)
-
Patent number: 8940293Abstract: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).Type: GrantFiled: April 20, 2011Date of Patent: January 27, 2015Assignee: Henry Ford Health SystemInventors: Yi Li, Michael Chopp
-
Patent number: 8936908Abstract: The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.Type: GrantFiled: March 7, 2006Date of Patent: January 20, 2015Assignee: CEVEC Pharmaceuticals GmbHInventors: Gudrun Schiedner, Christoph Volpers
-
Publication number: 20150017139Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.Type: ApplicationFiled: July 18, 2014Publication date: January 15, 2015Inventors: Yadong Huang, Karen Ring
-
Patent number: 8927276Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.Type: GrantFiled: February 17, 2010Date of Patent: January 6, 2015Assignee: Cellin Technologies OUEInventors: Kaia Palm, Toomas Neuman
-
Publication number: 20150005369Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.Type: ApplicationFiled: July 8, 2014Publication date: January 1, 2015Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
-
Patent number: 8921107Abstract: The present invention provides a method for differentiating human neural progenitor cells into dopaminergic neurons, comprising the step of culturing human neural progenitor cells in a medium containing fusaric acid. In addition, the present invention provides a medium for differentiation of human neural progenitor cells into dopaminergic neurons.Type: GrantFiled: June 7, 2011Date of Patent: December 30, 2014Assignee: College of Medicine Pochon Cha University Industry-Academic Corportaion FoundationInventor: Ji-Sook Moon
-
Patent number: 8916382Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: May 19, 2014Date of Patent: December 23, 2014Assignee: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20140370007Abstract: This disclosure generally relates to cell-based therapies for treatment of visual disorders, including disorders of the cornea. Methods are exemplified for directed differentiation of corneal cells from stem cells. Compositions of corneal endothelial cells and uses thereof are also provided. Exemplary compositions exhibit improved cell density and/or more “youthful” gene expression relative to cells obtained from donated tissue.Type: ApplicationFiled: December 6, 2012Publication date: December 18, 2014Applicant: Advanced Cell Technology, Inc.Inventors: Kathryn L. McCabe, Shi-Jiang Lu, Robert P. Lanza
-
Publication number: 20140370596Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.Type: ApplicationFiled: July 21, 2014Publication date: December 18, 2014Inventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
-
Publication number: 20140356960Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.Type: ApplicationFiled: April 25, 2014Publication date: December 4, 2014Inventor: Imre Berger
-
Publication number: 20140356291Abstract: IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell lines for the screening and identification of candidate therapeutic targets.Type: ApplicationFiled: December 10, 2012Publication date: December 4, 2014Applicant: DUKE UNIVERSITYInventors: Hai Yan, Darell D. Bigner
-
Publication number: 20140356951Abstract: This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.Type: ApplicationFiled: July 24, 2014Publication date: December 4, 2014Inventors: Tayaramma Thatava, Andre Terzic, Yogish C. Kudva, Yasuhiro Ikeda
-
Patent number: 8895301Abstract: A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.Type: GrantFiled: January 27, 2012Date of Patent: November 25, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Su-Chun Zhang, Xiaoqing Zhang
-
Patent number: 8889415Abstract: A method for expanding human corneal endothelial cells includes: (a) providing an amniotic membrane with or without amniotic cells, wherein the amniotic membrane has an extracellular matrix; (b) placing onto the amniotic membrane, a sheet of endothelial layer, or a cell suspension including human corneal endothelial stem cells; and (c) culturing the corneal endothelial cells on the amniotic membrane for a duration sufficient for the corneal endothelial stem cells to expand to an appropriate area. The invention also relates to a method for creating a surgical graft for a recipient site of a patient using the method for expanding human corneal endothelial cells, and the surgical graft prepared therefrom.Type: GrantFiled: April 30, 2007Date of Patent: November 18, 2014Inventor: Ray Jui-Fang Tsai
-
Patent number: 8883716Abstract: Devices and methods for treating diseases associated with loss of neuronal function are described. The methods are designed to promote proliferation, differentiation, migration, or integration of endogenous progenitor stem cells of the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region containing endogenous stem cells or a CNS region where the endogenous stem cells are predicted to migrate and eventually reside, or a combination thereof.Type: GrantFiled: December 7, 2011Date of Patent: November 11, 2014Assignee: Medtronic, Inc.Inventor: Lisa L. Shafer
-
Publication number: 20140322176Abstract: The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided.Type: ApplicationFiled: March 14, 2014Publication date: October 30, 2014Applicant: Elixirgen, LLCInventor: Minoru S.H. KO
-
Publication number: 20140322179Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.Type: ApplicationFiled: July 11, 2014Publication date: October 30, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michel Revel, Judith Chebath, Michal Izrael, Rosalia Kaufman
-
Patent number: 8871507Abstract: This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.Type: GrantFiled: November 26, 2013Date of Patent: October 28, 2014Assignees: California State University, Fresno, California State University, FullertonInventor: Santanu Maitra
-
Publication number: 20140315234Abstract: The present invention relates to a method for reprogramming a differentiated non neuronal cell into a dopaminergic neuron comprising the step of inducing the expression in the differentiated non neuronal cell of at least the protein encoded by the Mash1 human gene or orthologues thereof and the protein encoded by the Nurr1 human gene or orthologues thereof, expression vectors, reprogrammed dopaminergic neuron and uses thereof.Type: ApplicationFiled: December 13, 2011Publication date: October 23, 2014Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Vania Broccoli, Massimiliano Caiazzo
-
Patent number: 8859281Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.Type: GrantFiled: September 23, 2013Date of Patent: October 14, 2014Assignee: Bell Biosystems, Inc.Inventors: Caleb B. Bell, III, Alexey Bazarov
-
Publication number: 20140294778Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.Type: ApplicationFiled: March 14, 2014Publication date: October 2, 2014Applicant: Advanced Cell Technology, Inc.Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
-
Publication number: 20140295547Abstract: A method to construct an in-vitro human blood brain barrier (BBB) model is disclosed, which comprises steps: attaching suspension liquids of human brain vascular pericytes (HBVPs) and human astrocytes (HAs) by a ratio of 1:1, 1:2, or 1:6 to a bottom surface of a filter membrane of a culture dish to plant HBVPs and HAs on the bottom surface; filling a suspension liquid of human brain microvascular endothelial cells (HBMECs) into a top surface of the filter membrane to plant HBMECs on the top surface; placing the culture dish in a well plate containing a culture medium, and placing the well plate in a carbon-dioxide incubator; replacing the culture medium with a condition medium; and replacing the condition medium once daily for a plurality of days. Thereby is constructed an in-vitro human BBB model of high medical research availability.Type: ApplicationFiled: August 23, 2013Publication date: October 2, 2014Applicant: National Chung Cheng UniversityInventors: Yung-Chih KUO, Chin-Lung LEE
-
Publication number: 20140275222Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.Type: ApplicationFiled: November 9, 2012Publication date: September 18, 2014Applicants: Shire Human Genetic Therapies, Inc., University of KentuckyInventors: Stefan Stamm, Manli Shen, Serene Josiah
-
Patent number: 8835168Abstract: A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more human muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a human muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.Type: GrantFiled: May 6, 2011Date of Patent: September 16, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: James Hickman, Xiufang Guo
-
Patent number: 8828721Abstract: The present invention provides a method of inducing myelination of isolated motoneurons by preparing a non-biological substrate having thereon a covalently attached monolayer of DETA; depositing isolated motoneurons on the substrate in a defined serum-free medium; plating isolated Schwann cells cultured in the defined serum-free medium onto the motoneurons, thereby initiating a co-culture; and passaging the co-culture as necessary into fresh, defined serum-free medium supplemented with L-ascorbic acid at least until the motoneurons form Nodes of Ranvier indicative of myelination. The invention also includes a method of testing for new drugs effective in demyelinating diseases. Additionally, cellular products provided by the invention include an isolated motoneurons myelinated or remyelinated in vitro according to the methods disclosed.Type: GrantFiled: May 27, 2010Date of Patent: September 9, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: James Hickman, John Rumsey
-
Patent number: 8822216Abstract: The present invention provides for a method of evaluating whether a compound is effective in activating a calcium-calmodulin dependent kinase II? promoter in a human neuronal cell which comprises: (a) contacting the human neuronal cell which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase II? promoter which has a nucleotide sequence of the promoter in ATCC Accession No. 98582 with the compound, and (b) comparing the expression level of the gene of interest in the neuronal cell in step (a) with the level in the neuronal cell in the absence of the compound, thereby determining whether the compound is effective in activating the calcium-calmodulin dependent kinase II? promoter.Type: GrantFiled: February 29, 2012Date of Patent: September 2, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Eric R. Kandel, Mark Mayford
-
Patent number: 8815589Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.Type: GrantFiled: May 9, 2012Date of Patent: August 26, 2014Assignee: The J. David Gladstone InstitutesInventors: Yadong Huang, Karen Ring
-
Patent number: 8809052Abstract: A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.Type: GrantFiled: August 15, 2007Date of Patent: August 19, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Michel Revel, Judith Chebath, Michal Izrael, Rosalia Kaufman
-
Publication number: 20140227272Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Patent number: 8790666Abstract: The present invention relates to mechanically elongated neurons and provides useful compositions, devices and methods for treating a nerve lesion using such mechanically elongated neurons.Type: GrantFiled: May 5, 2006Date of Patent: July 29, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: Douglas H. Smith
-
Publication number: 20140206037Abstract: A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.Type: ApplicationFiled: November 22, 2013Publication date: July 24, 2014Inventors: Roderick A Slavcev, Nafiseh Nafissi
-
Patent number: 8785187Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.Type: GrantFiled: June 9, 2005Date of Patent: July 22, 2014Assignee: The University Court of the University of EdinburghInventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
-
Patent number: 8778680Abstract: A method of differentiating adult stem cells, such as those derived from a teratocarcinoma cell line, the Ntera2/D1 clone (NT2). The developed cells exhibit a stable neurotransmitter phenotype without the required use of growth factors or retinoic acid in differentiation process, which may be difficult to completely remove during commercial production. An identification of specific neurotransmitters is possible in these differentiated NT2-derived neurons (NT2-N) after 30 days in culture or 30 days survival in vivo. The invention includes a method to stably differentiate neuronal stem/precursor cells to a neuronal phenotype for use in cell replacement therapy for neurodegenerative disease, stroke or spinal cord injury. At least four different types of neurons are produced from this method of differentiation: dopaminergic, cholinergic, GABAergic and glutaminergic.Type: GrantFiled: December 28, 2007Date of Patent: July 15, 2014Assignee: University of South FloridaInventors: Samuel Saporta, Elise Spencer, Rania Shamekh
-
Publication number: 20140193836Abstract: The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Cc17, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.Type: ApplicationFiled: July 27, 2012Publication date: July 10, 2014Applicants: EISAI R&D MANAGEMENT CO., LTD., KYOTO UNIVERSITYInventors: Jun Takahashi, Daisuke Doi, Bumpei Samata, Yuichi Ono
-
Publication number: 20140193341Abstract: A method for reprogramming a fibroblast into a human induced neuronal cell (hIN) is described. The method comprises expressing heterologous reprogramming factors Bm2, Myt11, Zic1, Olig2, Asc11 or any combination thereof, in said fibroblast, and culturing the fibroblast in a medium comprising BDNF, NT3, GeM or any combination thereof. Biomarkers describing the obtained hiN cells are also presented. In another aspect, methods for screening compounds using the hiN cells is described.Type: ApplicationFiled: January 19, 2012Publication date: July 10, 2014Inventors: Asa Abeliovich, Liang Qiang
-
Patent number: 8771935Abstract: The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunction and for enhancing memory or normal cognitive performance (ability or function) in the animal.Type: GrantFiled: February 2, 2012Date of Patent: July 8, 2014Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Timothy P Tully, Roderick E. M. Scott, Rusiko Bourtchouladze
-
Publication number: 20140186391Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.Type: ApplicationFiled: March 22, 2013Publication date: July 3, 2014Applicant: CRUCELL HOLLAND B.V.Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
-
Publication number: 20140186309Abstract: Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.Type: ApplicationFiled: May 17, 2012Publication date: July 3, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Henry Klassen, Jing Yang
-
Publication number: 20140162936Abstract: The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)A(X2)(X3)(X4)(X5) (X6)LSFHKGEKFQIL(X7 (X8)(X9)(X10) (X11)(X12)G(X13)(X14)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is R, N, Q, E, K, H, S, T, C, or D; (X2) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X3) is R, T, H, N, K, S, C, N or Q; (X4) is S, W, T, C, N, Q, For Y; (X5) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X6) is D, Q, H, E, S, T, C, N, R or K; (X7) is D, N, R, E, Q, S, T, C, K or D; (X8) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X9) is T, H, S, D, C, N, Q, R, K, E or absent; (X10) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X11) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X12) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X13) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X14) is W, Y, L, G, A, V, I, P, M, or F; (b)Type: ApplicationFiled: April 24, 2012Publication date: June 12, 2014Applicant: COVAGEN AGInventors: Simon Brack, Sarah Batey, Dragan Grabulovski, Julian Bertschinger, Daniel Schlatter, Jörg Benz, David Banner, Michael Hennig
-
Patent number: 8747880Abstract: An engineered three-dimensional structure includes living cells cohered with each other. The living cells suitably include Schwann cells and at least one other type of cell. The cells accompanying the Schwann cells can suitably be bone marrow stem cells or another type of cell having one or more anti-inflammatory properties. The structure is suitably a graft that facilitates restorative axon growth when the graft is implanted between the proximal and distal stubs of a severed nerve in a living organism. The graft can optionally include a plurality of acellular conduits extending between opposite axial ends of the graft. Bio-printing techniques can be used to assemble a three-dimensional construct that becomes through maturation an axon-guiding graft, by stacking a plurality of multicellular bodies, each of which includes a plurality of living cells cohered to one another to sufficiently to avoid collapsing when the multicellular bodies are stacked to form the structure.Type: GrantFiled: February 2, 2011Date of Patent: June 10, 2014Assignee: The Curators of the University of MissouriInventors: Gabor Forgacs, Stephen H. Colbert, Bradley A. Hubbard, Francoise Marga, Dustin Christiansen
-
Publication number: 20140154800Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: H. Bion Co., Ltd.Inventors: Sung-Il ROH, Woo-Suk HWANG, Byeong-Chun LEE, Sung-Keun KANG, Young-June RYU, Eu-Gene LEE, Soon-Woong KIM, Dae-Kee KWON, Hee-Sun KWON, Ja-Min KOO, Eul-Soon PARK, Youn-Young HWANG, Hyun-SOO YOON, Jong-Hyuk PARK, Sun-Jong KIM
-
Publication number: 20140140965Abstract: The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Applicant: The Schepens Eye Research InstituteInventors: Michael J. Young, Budd A. Tucker, Petr Y. Baranov
-
Patent number: 8728818Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: October 5, 2012Date of Patent: May 20, 2014Assignee: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20140134729Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.Type: ApplicationFiled: July 19, 2013Publication date: May 15, 2014Applicant: GERON CORPORATIONInventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
-
Publication number: 20140127800Abstract: In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.Type: ApplicationFiled: March 11, 2013Publication date: May 8, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Eric V. Shusta, Sean P. Palecek, Ethan S. Lippmann, Samira M. Azarin
-
Patent number: 8716216Abstract: A composition of an immunosuppressant protein (HISP) which is achieved by the steps of obtaining supernatant from hNT neuronal cells; exposing the supernatant to preparative polyacrylamide gel; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells.Type: GrantFiled: May 9, 2008Date of Patent: May 6, 2014Assignee: University of South FloridaInventors: Robert W. Engelman, William R. Gower, Paul R. Sanberg
-
Patent number: 8709807Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.Type: GrantFiled: March 30, 2012Date of Patent: April 29, 2014Assignee: University of Utah Research FoundationInventors: Margot Mayer-Proschel, Mahendra S. Rao, Patrick A. Tresco, Darin J. Messina
-
Publication number: 20140093957Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.Type: ApplicationFiled: December 28, 2011Publication date: April 3, 2014Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
-
Publication number: 20140080209Abstract: This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.Type: ApplicationFiled: November 26, 2013Publication date: March 20, 2014Applicant: California State University FresnoInventor: Santanu Maitra
-
Patent number: 8673594Abstract: This invention relates to the novel identification of arginase as an enzymatic activity which can reverse inhibition of neuronal regeneration in the central and peripheral nervous system. Assays to monitor the effects of various agents on arginase expression and thus on neuronal regeneration and repair and to identify agents which will block or promote the inhibitory effects on neuronal outgrowth are provided. This invention also relates to compositions and methods using agents that can reverse the inhibitory effects of myelin on neural regeneration by affecting arginase activity or putrescine and derivative polyamine levels in a neuron.Type: GrantFiled: November 5, 2009Date of Patent: March 18, 2014Assignees: Research Foundation of City University of New York, Beth Israel Deaconness Medical CenterInventors: Marie T. Filbin, Rajiv R. Ratan